IS8587A - Atorvastatin pharmaceutical combination - Google Patents

Atorvastatin pharmaceutical combination

Info

Publication number
IS8587A
IS8587A IS8587A IS8587A IS8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A IS 8587 A IS8587 A IS 8587A
Authority
IS
Iceland
Prior art keywords
pharmaceutical combination
atorvastatin pharmaceutical
atorvastatin
combination
pharmaceutical
Prior art date
Application number
IS8587A
Other languages
Icelandic (is)
Inventor
Jóhannsson Fjalar
Original Assignee
Actavis Group Hf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Hf. filed Critical Actavis Group Hf.
Priority to IS8587A priority Critical patent/IS8587A/en
Priority to EP07849693A priority patent/EP2124899A2/en
Priority to PCT/IS2007/000024 priority patent/WO2008078341A2/en
Publication of IS8587A publication Critical patent/IS8587A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS8587A 2006-12-27 2006-12-27 Atorvastatin pharmaceutical combination IS8587A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IS8587A IS8587A (en) 2006-12-27 2006-12-27 Atorvastatin pharmaceutical combination
EP07849693A EP2124899A2 (en) 2006-12-27 2007-12-21 Stable pharmaceutical formulations of atorvastatin magnesium salt
PCT/IS2007/000024 WO2008078341A2 (en) 2006-12-27 2007-12-21 Stable pharmaceutical formulations of atorvastatin magnesium salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS8587A IS8587A (en) 2006-12-27 2006-12-27 Atorvastatin pharmaceutical combination

Publications (1)

Publication Number Publication Date
IS8587A true IS8587A (en) 2008-06-28

Family

ID=39473858

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8587A IS8587A (en) 2006-12-27 2006-12-27 Atorvastatin pharmaceutical combination

Country Status (3)

Country Link
EP (1) EP2124899A2 (en)
IS (1) IS8587A (en)
WO (1) WO2008078341A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130819A3 (en) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Crystalline forms of atorvastatin magnesium

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475722A1 (en) * 2002-02-14 2003-08-21 Romi Barat Singh Formulations of atorvastatin stabilized with alkali metal additions
WO2006054308A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1833466A1 (en) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
ES2304911T3 (en) * 2005-05-03 2011-05-30 Ranbaxy Laboratories Limited MAGNETIC SALES OF INHIBITORS OF THE HMG-COA REDUCTASE.
JP2009517459A (en) * 2005-11-29 2009-04-30 バイオコン・リミテッド [R- (R *, R *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- Polymorph of 1H-pyrrole-1-heptanoic acid magnesium salt (2: 1)
SI22255A (en) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New polymorphs of statine salts and their application in pharmaceutical formulations
CN101516842A (en) * 2006-05-11 2009-08-26 百康有限公司 A crystalline form B4 of atorvastatin magnesium and a process thereof

Also Published As

Publication number Publication date
WO2008078341A2 (en) 2008-07-03
WO2008078341A3 (en) 2008-12-24
EP2124899A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
DK2041139T3 (en) Pharmaceutical compounds
LTC2140867I2 (en) Pharmaceutical composition
BRPI0715712A2 (en) PHARMACEUTICAL COMPOSITION
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
BRPI0719393A2 (en) Pharmaceutical Composition
DK2343071T3 (en) Pharmaceutical dosage forms
BRPI0721651A2 (en) PHARMACEUTICAL COMPOSITION
BRPI0920521A2 (en) pharmaceutical combination
DK2073795T3 (en) Abuse-safe drug formulation
DK1986650T3 (en) MANIPULATION-SAFE DOSAGE FORMS
RU2398586C3 (en) PHARMACEUTICAL COMPOSITION
CR10841A (en) IMIDAZOTRIAZINAS IMIDAZOPIRIMIDINAS INHIBIDORES DE CINASA
AT504580A3 (en) SCAN-DEVICE
BRPI0720234A2 (en) PHARMACEUTICAL COMPOSITION
BRPI0716445A2 (en) pharmaceutical composition
EP2091731A4 (en) PREPREG-LAMINATE
DK2120884T3 (en) Pharmaceutical composition
DK2035369T3 (en) THERAPEUTIC
BRPI0717939A2 (en) AMINOMETIL-4-IMMIDAZOIS
PT2209464E (en) ANTIMALARIC PHARMACEUTICAL COMPOSITION
DK1957073T3 (en) PHARMACEUTICAL
DE502007000361D1 (en) Stanznieteinheit
BRPI0716742A2 (en) Therapeutic Lactams
DE112007003147A5 (en) Pipe-bender
BRPI0719956A2 (en) RADIOFLUORATION